RFK JR. grilled on Medicare: What is Medicare Part A, Medicare Part B and Medicaid? What are they?
Senators grilled Robert F. Kennedy Jr. on if and how he would reform Medicaid and Medicare during his first confirmation hearing to become the next secretary of Health and Human Services.
RFK Jr. second hearing takeaways: GOP criticism, more Medicare fumbles, and DEI
RFK Jr.'s second Senate confirmation hearing focused on vaccines, Medicare, diversity, and science. Key Republicans were reticent to show support.
RFK Jr. Has a Lot to Learn About Medicaid
Put on the spot, a lot of Americans might hesitate over the difference between Medicaid and Medicare. People who aren’t affected by one of these programs, which together enroll about 150 million people in the U.
RFK Jr. stumbles on Medicaid at Senate confirmation hearing
Robert F. Kennedy Jr., Trump’s nominee to lead HHS, stumbled multiple times during his first Senate confirmation hearing when asked about Medicaid.
RFK Jr. Confused Medicare and Medicaid: Here's the Difference
The HHS Secretary nominee confused Medicare and Medicaid programs, though he would be responsible for them. We break down the difference.
Robert F. Kennedy Jr. struggles to answer questions on Medicare and Medicaid at confirmation hearing
Kennedy's misstatements about the program were peppered in between suggestions that he would seek to push privatization of the programs.
RFK Jr. hearing reveals Kennedy’s inconsistent stance on Medicare and Medicaid
Kennedy made inaccurate claims about Medicare and Medicaid during his confirmation hearing.
‘Confused medicare and medicaid’: Doctor shares concerns on RFK Jr.
Today is Robert F. Kennedy Jr.‘s confirmation hearing for Secretary of Health and Human Services. NBC News’ Vaughn Hillyard reports and Andrea Mitchell speaks with Dr. Kavita Patel about her concerns about his nomination.
Trump order signals shake-up in drug pricing innovation through Medicare and Medicaid
President Donald Trump’s Day One executive order rescinding Biden-era Medicare and Medicaid price innovation programs signals ...
CNN on MSN13d
Ozempic and Wegovy selected for next round of Medicare drug price negotiations
Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will ...
wqad9d
Yes, Trump rescinded Biden's order to lower prescription drug costs for people on Medicare and Medicaid
The final proposed model would have had Medicare pay less for drugs that receive accelerated approvals from the Food and ...
Does Medicare cover ketamine infusions for mental health conditions?
Because it is still awaiting approval, Medicare does not typically cover the use of ketamine infusion for treating mental ...
CMS to seek Medicare negotiations on Ozempic price
The Centers for Medicare and Medicaid Services (CMS) has included Ozempic among the next 15 drugs chosen for Medicare ...
JD Supra7h
Rethinking FDA’s Accelerated Approval Pathway: New Draft Guidances and Implications for Drug Companies
The U.S. Food and Drug Administration (FDA) recently issued two new guidance documents governing details of the Accelerated Approval ...
Medicare to negotiate price of Ozempic, Wegovy weight-loss drugs
Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.
Ozempic, Wegovy among drugs selected for Medicare's price negotiations
The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare ...
The Hill on MSN13d
Biden administration picks 15 more drugs for Medicare negotiation
“I need to remind people the President made a pretty direct promise more than four years ago, when he was campaigning […], he ...
Does Medicare cover estradiol cream?
Medicare Part D prescription drug plans may cover estradiol cream. A person can check with their plan to confirm coverage.
Vertex Pharmaceuticals Shares Gain After FDA Approves Non-Opioid Pain Drug
Shares of Vertex Pharmaceuticals rose after Journavx, the company's oral non-opioid pain medication, received Food and Drug Administration approval. The Boston company's stock rose 4.3%, to $457.25, ...